Results 71 to 80 of about 186,086 (209)

Inhibiting FAT1 Blocks Metabolic Bypass to Enhance Antitumor Efficacy of TCA Cycle Inhibition through Suppressing CPT1A‐Dependent Fatty Acid Oxidation

Advanced Science, EarlyView.
This study demonstrates that mutant FAT1 promotes ASCL2‐driven, CPT1A‐dependent fatty acid oxidation, leading to resistance to CPI‐613‐mediated TCA cycle inhibition in head and neck cancer. In vivo gene depletion of mutant FAT1 with LNP‐sgFAT1 suppresses tumor growth and restores CPI‐613 sensitivity, revealing a targetable metabolic bypass with ...
Fanghui Chen, Jianqiang Yang, David O. Popoola, Fan Yang, Yajie Liu, Dongsheng Wang, Zhaohui S. Qin, Zhengjia Chen, Nabil F. Saba, Zhuo G. Chen, Yamin Li, Yong Teng   +11 more
wiley   +1 more source

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) [PDF]

, 2008
Acute myeloid leukemia with mutated NPM1 gene and aberrant cytoplasmic expression of nucleophosmin (NPMc+acute myeloid leukemia) shows distinctive biological and clinical features.
A. Cappuccio, A. Ganser, A. Liso, B. Falini, B. Lö, C. Thiede, F. Castiglione, F. Mandelli, F. Michor, F. Stracci, G. Ehninger, H. Dö, J. Krauter, K. Dö, M. Schaich, M.F. Martelli, M.P. Martelli, N. Bolli, P.J..M. Valk, R.F. Schlenk, S. Amadori, S. Schnittger, T. Haferlach   +22 more
core   +2 more sources

Fast pH‐Driven Solubilization Method of Realgar (As4S4) to Reduce the Toxicity of Arsenic [As(III)] for Medicinal Purposes

Advanced Science, EarlyView.
Arsenic trioxide transformed acute promyelocytic leukemia therapy and shows promise against HIV. A new method to solubilize the mineral realgar produces different arsenic species depleting the main arsenic target, nuclear PML protein, and retaining effects on leukemic and HIV reservoir cells, while minimizing off‐target damage.
Bojana Lucic, Douglas Santana Franciscato, Helton Pereira Nogueira, Lara Gallucci, Alceu Totti Silveira Junior, Asmaa Mohamed Ismail, Millie Robinson, Teresa Dallinger, Claudia Gutfleisch, Jochen Kurz, Maytê Toledo, Jessica Dias da Silva Ferraz, Mohammad Tarek, Danilo Dias, Ricardo Sobhie Diaz, Mahmoud ElHefnawi, Mattia Forcato, Hugo P Monteiro, Marina Lusic, Iart Luca Shytaj, Andrea Savarino   +20 more
wiley   +1 more source

Classification of acute myeloid leukemia

BLOOD RESEARCH, 2020
The World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues was revised in 2017 on the basis of recent high-throughput sequencing and gene expression data on hematologic malignancies. This review explores the current WHO classification of acute myeloid leukemia (AML) and related precursor neoplasms, highlighting ...
openaire   +4 more sources

Targeted Penetrating Motif Engineering of BH3 Mimetic: Harnessing Non‐Canonical Amino Acids for Coinhibition of MCL‐1 and BCL‐xL in Acute Myeloid Leukemia

Advanced Science, EarlyView.
A structure‐guided peptide derived from a non‐canonical amino acid library simultaneously targets MCL‐1 and BCL‐xL to overcome apoptotic resistance in acute myeloid leukemia. Fused with a CXCR4‐binding motif, the engineered peptide exhibits selective intracellular delivery and potent in vivo efficacy, offering a promising therapeutic strategy against ...
Zhe Wang, Ruizhi Lai, Xinpei Wang, Xu Chen, Youjian Zhou, Shengbin Li, Xiaohui Qiu, Zekai Zeng, Jianye Yuan, Jinghuan Mao, Zhidong Chen, Junqing Wang   +11 more
wiley   +1 more source

HoxA9 binds and represses the Cebpa +8 kb enhancer [PDF]

, 2019
C/EBPα plays a key role in specifying myeloid lineage development. HoxA9 is expressed in myeloid progenitors, with its level diminishing during myeloid maturation, and HOXA9 is over-expressed in a majority of acute myeloid leukemia cases, including those
Aplan, Peter D., Dennison, Lauren, Friedman, Alan D., Guo, Hong, Hess, Jay L., Ma, Peilin, Peng, Lei, Sun, Yuqing   +7 more
core   +2 more sources

Cryo‐Inactivated Cancer Cells Derived Magnetic Micromotors for Tumor Immunotherapy

Advanced Science, EarlyView.
Cryo‐inactivated cancer cell‐based magnetic micromotors are developed for synergistic tumor immunotherapy via magnetic targeting. These micromotors can induce ferroptosis and immunogenic cell death, deliver tumor antigens, and activate the Mn2+‐dependent cGAS‐STING pathway. The system effectively suppresses tumor progression, recurrence, and metastasis,
Qingfei Zhang, Gaizhen Kuang, Wenzhao Li, Yuanjin Zhao   +3 more
wiley   +1 more source

Biomarkers of leukemia risk: benzene as a model. [PDF]

, 1998
Although relatively rare, leukemias place a considerable financial burden on society and cause psychologic trauma to many families. Leukemia is the most common cancer in children.
Smith, MT, Zhang, L
core   +3 more sources

Models of chronic myeloid leukemia [PDF]

Current Oncology Reports, 2001
Models of chronic myeloid leukemia (CML) have proven invaluable for furthering our understanding of the molecular pathophysiology of this disease. Xenotransplantation of primary human CML cells into immunodeficient mice allows investigation into the nature of the most primitive repopulating cells in this leukemia, but the system is limited by ...
openaire   +3 more sources

A ROS‐Responsive Dual‐Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T‐Cell Acute Lymphoblastic Leukemia

Advanced Science, EarlyView.
A self‐assembling nanotherapeutic strategy is designed—CD38‐PHD/G‐NPs, which released γ‐secretase inhibitor first, followed by adaptive dihydroartemisnin release in response to elevated reactive oxygen species levels. This controlled, sequential release strategy maximizes the synergistic anti‐leukemic efficacy of two agents with distinct mechanisms of ...
Ruinan Jia, Yang Liu, Jilong Xiao, Yuan Xia, Xin Zhao, Huixian Ma, Jingjing Ye, Zhiyue Zhang, Tao Sun, Chunyan Ji   +9 more
wiley   +1 more source